{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:44:56Z","timestamp":1793151896361,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Epstein\u2013Barr virus (EBV) infects up to 95% of the adult human population, with primary infection typically occurring during childhood and usually asymptomatic. However, EBV can cause infectious mononucleosis in approximately 35\u201350% cases when infection occurs during adolescence and early adulthood. Epstein\u2013Barr virus is also associated with several B-cell malignancies including Burkitt lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease. A number of antiviral drugs have proven to be effective inhibitors of EBV replication, yet have resulted in limited success clinically, and none of them has been approved for treatment of EBV infections.<\/jats:p>","DOI":"10.3390\/cancers10060197","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T10:45:35Z","timestamp":1528886735000},"page":"197","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Antiviral Drugs for EBV"],"prefix":"10.3390","volume":"10","author":[{"given":"Joseph S.","family":"Pagano","sequence":"first","affiliation":[{"name":"Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-2317","authenticated-orcid":false,"given":"Christopher B.","family":"Whitehurst","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Andrei","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Leuven, BE-3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/infdis\/174.2.324","article-title":"Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled study","volume":"174","author":"Tynell","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0002-9343(82)90057-2","article-title":"Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses","volume":"73","author":"Pagano","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jac\/12.suppl_B.113","article-title":"Acyclovir and Epstein-Barr virus infection","volume":"12","author":"Pagano","year":"1983","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/jvi.34.2.560-568.1980","article-title":"Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication","volume":"34","author":"Colby","year":"1980","journal-title":"J. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1073\/pnas.72.4.1477","article-title":"Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells","volume":"72","author":"Adams","year":"1975","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jac\/dki240","article-title":"Epstein-Barr virus infections: Prospects for treatment","volume":"56","author":"Gershburg","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1099\/0022-1317-67-10-2267","article-title":"Acyclovir efficiently inhibits oropharyngeal excretion of Epstein-Barr virus in patients with acute infectious mononucleosis","volume":"67","author":"Ernberg","year":"1986","journal-title":"J. Gen. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jhep.2006.02.006","article-title":"The role of Epstein-Barr virus in acute and chronic hepatitis","volume":"44","author":"Drebber","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jhep.2006.03.002","article-title":"The paradox of Epstein-Barr virus-associated hepatitis","volume":"44","author":"Negro","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1620\/tjem.227.307","article-title":"Quantification of Epstein-Barr virus DNA is helpful for evaluation of chronic active Epstein-Barr virus infection","volume":"227","author":"Sakamoto","year":"2012","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1432-2277.2012.01485.x","article-title":"(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation","volume":"25","author":"Hocker","year":"2012","journal-title":"Transpl. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1053-2498(01)00407-7","article-title":"Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients","volume":"21","author":"Malouf","year":"2002","journal-title":"J. Heart Lung Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/lt.21498","article-title":"Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus","volume":"14","author":"Hierro","year":"2008","journal-title":"Liver Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ajt.12004","article-title":"Epstein-Barr virus infection and posttransplant lymphoproliferative disorder","volume":"13","author":"Green","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/ijc.22839","article-title":"Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease","volume":"121","author":"Jones","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/tri.13085","article-title":"Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: A retrospective cohort study","volume":"31","author":"Ville","year":"2018","journal-title":"Transpl. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/AAC.32.8.1137","article-title":"Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate","volume":"32","author":"Abele","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.45.6.1629-1636.2001","article-title":"Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine","volume":"45","author":"Ng","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1128\/JVI.73.9.7271-7277.1999","article-title":"Inhibition of Epstein-Barr virus replication by a benzimidazole l-riboside: Novel antiviral mechanism of 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl-1H-benzimidazole","volume":"73","author":"Zacny","year":"1999","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1128\/AAC.03214-14","article-title":"Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing","volume":"58","author":"Chou","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.01259-10","article-title":"Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility","volume":"55","author":"Chou","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/rmv.574","article-title":"Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir","volume":"18","author":"Chou","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12108","DOI":"10.1128\/JVI.01575-09","article-title":"Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication","volume":"83","author":"Wang","year":"2009","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.virol.2009.04.007","article-title":"Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase","volume":"389","author":"Murata","year":"2009","journal-title":"Virology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1128\/JVI.03505-12","article-title":"Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase","volume":"87","author":"Whitehurst","year":"2013","journal-title":"J. Virol."},{"key":"ref_29","first-page":"93","article-title":"Cidofovir in the treatment of HPV-associated lesions","volume":"63","author":"Snoeck","year":"2001","journal-title":"Verh. K. Acad. Geneeskd. Belg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jmv.21165","article-title":"Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir","volume":"80","author":"Yoshizaki","year":"2008","journal-title":"J. Med. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ijc.21096","article-title":"Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts","volume":"116","author":"Wakisaka","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1128\/JVI.03338-12","article-title":"Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses","volume":"87","author":"Coen","year":"2013","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1128\/AAC.02825-14","article-title":"Antiherpesvirus activities of two novel 4\u2032-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases","volume":"58","author":"Coen","year":"2014","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/6\/197\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:08:25Z","timestamp":1760195305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/6\/197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["cancers10060197"],"URL":"https:\/\/doi.org\/10.3390\/cancers10060197","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734602434.793556742","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,13]]}}}